Trial of Mistletoe Extract in Patients With Advanced Solid Tumors (NCT03051477) (2022)

Government Record · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (lead sponsor) · December 8, 2022

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (lead sponsor), 2022-12-08: ClinicalTrials.gov registration for the Johns Hopkins phase I intravenous mistletoe trial: completed 2022, sponsor Sidney Kimmel Comprehensive Cancer Center, no results posted.

This study will seek to determine the safety and toxicity profile as well as the maximum tolerated dose of Helixor® M in patients with advanced solid tumors.

Brief Summary field

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (lead sponsor), 2022-12-08: ClinicalTrials.gov registration for the Johns Hopkins phase I intravenous mistletoe trial: completed 2022, sponsor Sidney Kimmel Comprehensive Cancer Center, no results posted. Read through the API endpoint https://clinicaltrials.gov/api/v2/studies/NCT03051477, because the human study page is a JavaScript shell; the registered page is cited for the reader. 'hasResults' is false – registered, no posted results. 21 participants per the publication (CHG-32). ClinicalTrials.gov serves no PDF edition of a registration record, so pdf_url is empty. Federal record. Study type: other.